Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...

The stock market heads into the final week of June with an eye on Tesla, Novo Nordisk, defense stocks and weekly jobless ...

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

According to Benzinga Pro, Novo Nordisk's peer group average for short interest as a percentage of float is 4.03%, which ...

The global peptide therapeutics market size was valued at $33.3 billion in 2021, and is projected to reach $64.3 billion by 2031, growing at a CAGR o ...